Status:
COMPLETED
Efficacy and Tolerance Evaluation of a "Revitalizing" Face Treatment
Lead Sponsor:
Derming SRL
Conditions:
Face Aging/Photo Aging of Moderate Grade
Eligibility:
FEMALE
35-60 years
Phase:
NA
Brief Summary
Efficacy and Tolerance Evaluation of a"revitalizing" face treatment consisting of a day and a night cream
Detailed Description
Aim of the study was to evaluate clinically and by non-invasive instrumental evaluations the activity of a "revitalizing" face treatment consisting of a day and a night cream, applied for an uninterru...
Eligibility Criteria
Inclusion
- female sex,
- age 35-60 years,
- Caucasian subjects,
- presence of moderate face ritidosis,
- agreeing to present at each study visit without make-up,
- accepting to follow the instructions received by the investigator,
- accepting to not change their habits regarding food, physical activity, face cleansing and make- up use,
- agreeing not to apply or take any product or use face massages or other means known to improve skin wrinkle and skin qualities during the entire duration of the study,
- accepting not to expose their face to strong UV irradiation (UV session, or sun bathes), during the entire duration of the study,
- no participation in a similar study currently or during the previous 3 months
- accepting to sign the Informed consent form.
Exclusion
- Pregnancy,
- lactation,
- sensitivity to the test products or their ingredients (to be assessed by the investigator during the baseline visit),
- subjects whose insufficient adhesion to the study protocol is foreseeable.
- presence of cutaneous disease on the tested area as lesions, scars, malformations,
- recurrent facial/labial herpes,
- clinical and significant skin condition on the test area (e.g. active eczema, dermatitis, psoriasis etc.).
- endocrine disease,
- hepatic disorder,
- renal disorder,
- cardiac disorder,
- pulmonary disease,
- cancer,
- neurological or psychological disease,
- inflammatory/immunosuppressive disease,
- drug allergy.
- anti-inflammatory drugs, anti-histaminic, topic (application on the face) and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of hormonal treatment starting more than 1 year ago),
- using of drugs or dietary supplements able to influence the test results in the investigator opinion.
Key Trial Info
Start Date :
March 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2017
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT03276897
Start Date
March 21 2017
End Date
June 30 2017
Last Update
September 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
DERMING
Monza, Monza-brianza, Italy, 20900